1st QUARTER 2024
Reporting
Evonik has published its quarterly report Q1 2024 on May 8, 2024.
You can access further information here.
- Adj. EBITDA of €522 m clearly above prior year (+28% yoy) – even despite limited macro support so far
- Drivers of strong Q1 performance: Nutrition & Care with Animal Nutrition and strong Care Solutions portfolio; Specialty Additives with strong operating leverage from volumes coming back
- Contingency & optimization measures further ramping up; preparation for €400 m “Evonik Tailor Made” savings on track
- FCF of €127 m well above prior-year quarter, based on improved earnings and continued tight NWC management
- Outlook range for adj. EBITDA (€1.7 to 2.0 bn) confirmed – Q2 adj. EBITDA expected on Q1 level
Reporting 1st Quarter 2024
|
Document
|
Link / PDF
|
|
Analyst & Investor Factsheet
|
|
|
Presentation Conference Call
|
|
|
Detailed overview of key financial data (Evonik Financials) - as PDF |
|
|
Detailed overview of key financial data (Evonik Financials) - as Excel |
|
|
Quarterly Statement Q1 2024 |
|
|
Investor Relations News Q1 2024 |
|
|
Analysts' consensus* (Vara Research)
|
|
|
Webcast Conference Call Q1 2024 |
PRELIMINARY REPORTING 1st QUARTER 2024
|
Document |
Link / PDF |
|
Investor Relations News preliminary results Q1 2024 |
* The consensus is not controlled, changed or censored by Evonik Industries AG. Evonik Industries AG assumes no liability for the accuracy and completeness of these estimates and undertakes no obligation to update or revise such estimates and consensus data, even if they differ from Evonik Industries AG’s own forecasts or expectations. Evonik Industries AG is neither involved in the collection of the data, nor in the preparation of the consensus. This is done independently by Vara Research.